Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2024 08:00 ET | Source: Trian Fund Management, L.P.

Egan-Jones Recommends Disney Shareholders Vote “For” Nelson Peltz and Jay Rasulo

Joins ISS in Recognizing the Need for Board Change at Disney Egan-Jones Recommends Shareholders Vote “FOR” Nelson Peltz and Jay Rasulo and “WITHHOLD” on Maria Elena Lagomasino and Michael B.G....
March 26, 2024 16:10 ET | Source: Panbela Therapeutics, Inc.

Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results

MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
March 26, 2024 16:05 ET | Source: Annexon Biosciences

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024,...
March 25, 2024 08:15 ET | Source: Trian Fund Management, L.P.

Trian Reaffirms Its Call for Change at Disney and the Commitment of Its Director Candidates to Work Collaboratively with Members of the Disney Board

Emphasizes that the Election Contest is About Board Oversight, Not About Bob Iger Highlights its Candidates’ Extensive Track Records of Constructive Engagement with Corporate Boards and Management...
March 21, 2024 16:05 ET | Source: Cibus US LLC

Cibus Reports Fourth Quarter Financial Results and Provides Business Update

Completed successful transfers of gene edited elite germplasm back to customers for commercialization for each of its three developed productivity traits: Pod Shatter Reduction (PSR) in Canola and...
March 21, 2024 16:01 ET | Source: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) initiated in Q1’24 with top-line results anticipated in 2H’25 $389 million of pro forma cash, including $216 million of net proceeds from a...
March 21, 2024 12:34 ET | Source: Trian Fund Management, L.P.

Leading Proxy Advisory Firm ISS Recommends Disney Shareholders Vote “FOR” Nelson Peltz at Disney’s Annual Meeting

ISS Cites Disney’s Operating and Stock Underperformance, Succession Failures and the Board’s Need to Improve its Effectiveness Endorses Nelson Peltz as “Best Positioned” to Provide the Catalyst the...
March 21, 2024 07:00 ET | Source: Destination XL Group, Inc.

Destination XL Group, Inc. Reports Fiscal 2023 Fourth Quarter and Full-Year Financial Results

CANTON, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Destination XL Group, Inc. (NASDAQ: DXLG), the largest integrated commerce specialty retailer of Big + Tall men’s clothing and shoes, today reported...
March 18, 2024 13:38 ET | Source: Trian Fund Management, L.P.

Trian Sends Letter to Fellow Disney Shareholders Outlining the Need for Change

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- The Trian Group,1 which beneficially owns $3.5 billion of common stock in The Walt Disney Company (NYSE: DIS), today released a letter to its fellow...
March 12, 2024 21:30 ET | Source: Regeneron Pharmaceuticals, Inc.

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

TARRYTOWN, N.Y. and WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Achyuta...